Marker Therapeutics (MRKR) EBITDA (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly EBITDA of -$4.1 million for Q1 2026, up 17.86% year-over-year from -$3.5 million in Q1 2025, and down 116.16% quarter-over-quarter from -$1.9 million in Q4 2025.
Marker Therapeutics (MRKR) EBITDA (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported EBITDA for 17 consecutive years, with -$4.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA rose 17.86% year-over-year to -$4.1 million; the TTM figure through Mar 2026 stood at -$12.4 million (up 8.67% YoY), while the FY2025 annual figure was -$12.9 million, down 15.94% from the prior year.
- EBITDA retreated to -$4.1 million in Q1 2026 per MRKR's latest filing, from -$1.9 million in the prior quarter.
- Across five years, EBITDA topped out at -$1.9 million in Q4 2025 and bottomed at -$9.8 million in Q1 2022.
- Historically, EBITDA has averaged -$3.9 million across 5 years, with a median of -$3.9 million in 2024.
- Annual changes were most pronounced in 2022 — EBITDA surged 68.88% — and 2025, when it sank 94.5%.
- Marker Therapeutics' EBITDA stood at -$3.0 million in 2022, then rose by 3.32% to -$2.9 million in 2023, then sank by 31.44% to -$3.9 million in 2024, then soared by 51.21% to -$1.9 million in 2025, then slumped by 116.16% to -$4.1 million in 2026.
- Business Quant data shows MRKR's EBITDA at -$4.1 million in Q1 2026, -$1.9 million in Q4 2025, and -$2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Marker Therapeutics | 23.95 Mn | 12.02 Mn | - | -2.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.07 Mn |
| Dec 31, 2025 | -1.88 Mn |
| Sep 30, 2025 | -2.14 Mn |
| Jun 30, 2025 | -4.26 Mn |
| Mar 31, 2025 | -4.96 Mn |
| Dec 31, 2024 | -3.86 Mn |
| Sep 30, 2024 | -2.40 Mn |
| Jun 30, 2024 | -2.31 Mn |
| Mar 31, 2024 | -2.55 Mn |
| Dec 31, 2023 | -2.94 Mn |
| Sep 30, 2023 | -3.20 Mn |
| Jun 30, 2023 | -4.13 Mn |
| Mar 31, 2023 | -4.31 Mn |
| Dec 31, 2022 | -3.04 Mn |
| Sep 30, 2022 | -5.83 Mn |
| Jun 30, 2022 | -5.27 Mn |
| Mar 31, 2022 | -9.79 Mn |
| Dec 31, 2021 | -9.76 Mn |
| Sep 30, 2021 | -10.02 Mn |
| Jun 30, 2021 | -10.91 Mn |